셀트리온

068270KOSPI기초 의약물질 제조업

57.5 / 100

Reference Date: 2026-07-24

Financial Score21.0 / 40

News Sentiment18.5 / 25

Momentum6.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Celltrion is a global biotech company specializing in developing and commercializing biopharmaceuticals for autoimmune diseases and oncology, with 11 globally approved biosimilar products, including its first biosimilar, Remsima (CT-P13). It has expanded its global presence through strong market dominance in Europe and the U.S., and secured FDA approval for its subcutaneous infliximab formulation in 2023, aiming for 41.625 trillion KRW in sales by 2025.

Number of Employees

3,153people

Average Salary

108.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

36.89Industry Average 25.443.0Point

Higher than industry avg (caution)

PBR

2.31Industry Average 1.261.0Point

1.8x industry avg (risky)

ROE

5.91Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

3.05Industry Average 6.626.5Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲40.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲56.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 4.5% (improving, 3yr)

Detailed News Sentiment

64 totalPositive 45Neutral 15Negative 4Average Sentiment Score 73.8

Positive
삼성바이오·셀트리온 호실적…'K바이오 양대산맥' 매출 5조시대 연다
셀트리온의 실적이 컨센서스를 상회하며 K바이오 분야의 성장을 주도하고 있다.
Neutral
투자자가 묻다... 사상 최대 실적 다음 단계는[와이즈버즈 대해부③]
Neutral
'YTN 대주주 변경 취소' 심의, 없던 절차가 계속 추가된 이유?
YTN 대주주 변경 심의 과정의 복잡성으로 인해 셀트리온과 직접적인 연관성이 없다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 172,200Won52-week high 248,50052-week low 160,500

1-month return3.0Point

1m -0.29% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

66 totalPositive 1Neutral 65Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-16
Neutral투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 변경신청(Part1&2))2026-07-14
Neutral투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 유럽 임상 3상 조기종료 및 시험계획 자진취하)2026-07-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-07